Skip to main content
Top
Published in: Calcified Tissue International 3/2008

01-03-2008

Effects of Treatment with Parathyroid Hormone 1–84 on Quantity and Biomechanical Properties of Thoracic Vertebral Trabecular Bone in Ovariectomized Rhesus Monkeys

Authors: J. Fox, M. K. Newman, C. H. Turner, R. E. Guldberg, A. Varela, S. Y. Smith

Published in: Calcified Tissue International | Issue 3/2008

Login to get access

Abstract

Osteoporosis is characterized by impaired bone quality leading to increased susceptibility to fracture, particularly of the thoracic spine. However, the lumbar spine is studied most commonly. We investigated the effects of 16 months of treatment with full-length parathyroid hormone (PTH) 1–84 (5, 10, or 25 μg/kg) on bone mineral density (BMD) and on architecture and biomechanical properties of trabecular bone at the thoracic spine of ovariectomized (OVX) adult rhesus monkeys and compared the results with those from the lumbar spine. At baseline, 9 months after surgery, dual-energy X-ray absorptiometric BMD at T9–T12 was 7% lower in OVX than in sham animals. All PTH(1–84) doses increased BMD to sham levels within 7 months. Micro-computed tomography of T10 vertebrae showed that trabecular bone volume and connectivity were higher in PTH(1–84)-treated animals than in sham controls, primarily through a significantly greater trabecular number. Peripheral quantitative computed tomography of trabecular bone cores from T11 and T12 confirmed that PTH(1–84) increased BMD. Compression testing of the cores showed that PTH(1–84) treatment increased stiffness, modulus, yield load, and yield stress to levels significantly greater than in sham animals, with the largest effect in the 10 μg/kg group (35–54% greater than in OVX controls). Thus, PTH(1–84) treatment increased BMD and the biomechanical properties of trabecular bone at the thoracic spine of OVX rhesus monkeys. The 10 μg/kg dose produced the greatest effect on trabecular strength, possibly because the highest dose stimulated bone remodeling excessively. Importantly, the changes observed were similar to those in lumbar vertebrae, thereby validating extrapolation of results from the lumbar to the thoracic spine.
Literature
1.
go back to reference Cooper C, Atkinson EJ, Jacobsen SJ, O’Fallon WM, Melton LJ (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137:1001–1005PubMed Cooper C, Atkinson EJ, Jacobsen SJ, O’Fallon WM, Melton LJ (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137:1001–1005PubMed
2.
go back to reference Chapurlat RD, Duboeuf F, Marion-Audibert HO, Kalpakçioglu B, Mitlak BH, Delmas PD (2006) Effectiveness of instant vertebral assessment to detect prevalent vertebral fracture. Osteoporos Int 17:1189–1195PubMedCrossRef Chapurlat RD, Duboeuf F, Marion-Audibert HO, Kalpakçioglu B, Mitlak BH, Delmas PD (2006) Effectiveness of instant vertebral assessment to detect prevalent vertebral fracture. Osteoporos Int 17:1189–1195PubMedCrossRef
3.
go back to reference Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, Segal M, Genant HK, Cummings SR (1998) The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 128:793–800PubMed Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, Segal M, Genant HK, Cummings SR (1998) The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 128:793–800PubMed
4.
go back to reference Marcus R, Wong M, Heath H III, Stock JL (2002) Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 23:16–37PubMedCrossRef Marcus R, Wong M, Heath H III, Stock JL (2002) Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 23:16–37PubMedCrossRef
5.
go back to reference Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C (2002) IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570–578PubMedCrossRef Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C (2002) IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570–578PubMedCrossRef
6.
go back to reference McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF (2005) Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762–1768PubMedCrossRef McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF (2005) Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762–1768PubMedCrossRef
7.
go back to reference Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD (1998) Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102:1627–1633PubMedCrossRef Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD (1998) Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102:1627–1633PubMedCrossRef
8.
go back to reference Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF (2003) Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88:569–575PubMedCrossRef Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF (2003) Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88:569–575PubMedCrossRef
9.
go back to reference Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRef Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRef
10.
go back to reference Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB (2007) Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 146:326–339PubMed Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB (2007) Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 146:326–339PubMed
11.
go back to reference Keaveny TM, Donley DW, Hoffman PF, Mitlak BH, Glass EV, San Martin JA (2007) Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 22:149–157PubMedCrossRef Keaveny TM, Donley DW, Hoffman PF, Mitlak BH, Glass EV, San Martin JA (2007) Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 22:149–157PubMedCrossRef
12.
go back to reference Mosekilde L, Søgaard CH, Danielsen CC, Tørring O (1991) The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1–34) and hPTH-(1–84). Endocrinology 129:421–428PubMedCrossRef Mosekilde L, Søgaard CH, Danielsen CC, Tørring O (1991) The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1–34) and hPTH-(1–84). Endocrinology 129:421–428PubMedCrossRef
13.
go back to reference Kimmel DB, Bozzato RP, Kronis KA, Coble T, Sindrey D, Kwong P, Recker RR (1993) The effect of recombinant human (1–84) or synthetic human (1–34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 132:1577–1584PubMedCrossRef Kimmel DB, Bozzato RP, Kronis KA, Coble T, Sindrey D, Kwong P, Recker RR (1993) The effect of recombinant human (1–84) or synthetic human (1–34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 132:1577–1584PubMedCrossRef
14.
go back to reference Stewart AF, Cain RL, Burr DB, Jacob D, Turner CH, Hock JM (2000) Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1–34, parathyroid hormone-related protein 1–36, and SDZ-parathyroid hormone 893. J Bone Miner Res 15:1517–1525PubMedCrossRef Stewart AF, Cain RL, Burr DB, Jacob D, Turner CH, Hock JM (2000) Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1–34, parathyroid hormone-related protein 1–36, and SDZ-parathyroid hormone 893. J Bone Miner Res 15:1517–1525PubMedCrossRef
15.
go back to reference Fox J, Miller MA, Newman MK, Metcalfe AF, Turner CH, Recker RR, Smith SY (2006) Daily treatment of aged ovariectomized rats with human parathyroid hormone (1–84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength. Calcif Tissue Int 79:262–272PubMedCrossRef Fox J, Miller MA, Newman MK, Metcalfe AF, Turner CH, Recker RR, Smith SY (2006) Daily treatment of aged ovariectomized rats with human parathyroid hormone (1–84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength. Calcif Tissue Int 79:262–272PubMedCrossRef
16.
go back to reference Jerome CP, Burr DB, Van Bibber T, Hock JM, Brommage R (2001) Treatment with human parathyroid hormone (1–34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 28:150–159PubMedCrossRef Jerome CP, Burr DB, Van Bibber T, Hock JM, Brommage R (2001) Treatment with human parathyroid hormone (1–34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 28:150–159PubMedCrossRef
17.
go back to reference Binkley N, Kimmel D, Bruner J, Haffa A, Davidowitz B, Meng C, Schaffer V, Green J (1998) Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J Bone Miner Res 13:1775–1782PubMedCrossRef Binkley N, Kimmel D, Bruner J, Haffa A, Davidowitz B, Meng C, Schaffer V, Green J (1998) Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J Bone Miner Res 13:1775–1782PubMedCrossRef
18.
go back to reference Fox J, Miller MA, Newman MK, Turner CH, Recker RR, Smith SY (2007) Treatment of skeletally-mature ovariectomized rhesus monkeys with parathyroid hormone 1–84 for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine. J Bone Miner Res 22:260–273PubMedCrossRef Fox J, Miller MA, Newman MK, Turner CH, Recker RR, Smith SY (2007) Treatment of skeletally-mature ovariectomized rhesus monkeys with parathyroid hormone 1–84 for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine. J Bone Miner Res 22:260–273PubMedCrossRef
19.
go back to reference Fox J, Miller MA, Recker RR, Turner CH, Smith SY (2007) Effects of treatment of ovariectomized adult rhesus monkeys with parathyroid hormone 1–84 for 16 months on trabecular and cortical bone at the proximal femur. Calcif Tissue Int 81:53–63PubMedCrossRef Fox J, Miller MA, Recker RR, Turner CH, Smith SY (2007) Effects of treatment of ovariectomized adult rhesus monkeys with parathyroid hormone 1–84 for 16 months on trabecular and cortical bone at the proximal femur. Calcif Tissue Int 81:53–63PubMedCrossRef
20.
go back to reference Fox J, Miller MA, Newman MK, Turner CH, Recker RR, Smith SY (2007) Effects of daily treatment with parathyroid hormone (1–84) for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys. Bone 41:321–330PubMedCrossRef Fox J, Miller MA, Newman MK, Turner CH, Recker RR, Smith SY (2007) Effects of daily treatment with parathyroid hormone (1–84) for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys. Bone 41:321–330PubMedCrossRef
22.
go back to reference Smith SY, Recker R, Kimmel DB, Akhter M, Metcalfe A, Dietrich J (1998) Efficacy of recombinant human parathyroid hormone (1–84) (rhPTH, (1–84)) in ovariectomized rhesus monkeys. Bone 23:S633 Smith SY, Recker R, Kimmel DB, Akhter M, Metcalfe A, Dietrich J (1998) Efficacy of recombinant human parathyroid hormone (1–84) (rhPTH, (1–84)) in ovariectomized rhesus monkeys. Bone 23:S633
23.
go back to reference Fox J, Smith SY, Wells DS (2007) Pharmacokinetics and pharmacodynamics of human parathyroid hormone 1–84 in adult ovariectomized rhesus monkeys. J Bone Miner Res 22 Suppl 1:S439 Fox J, Smith SY, Wells DS (2007) Pharmacokinetics and pharmacodynamics of human parathyroid hormone 1–84 in adult ovariectomized rhesus monkeys. J Bone Miner Res 22 Suppl 1:S439
24.
go back to reference Littell RC, Stroup WW, Freund RJ (2002) SAS for linear models, 4th ed. SAS Press, Cary, NC, pp 256–261 Littell RC, Stroup WW, Freund RJ (2002) SAS for linear models, 4th ed. SAS Press, Cary, NC, pp 256–261
25.
go back to reference Peel NFA, Eastell RA (1995) Comparison of rates of bone loss using two manufacturers’ densitometers. J Bone Miner Res 10:1796–1801PubMedCrossRef Peel NFA, Eastell RA (1995) Comparison of rates of bone loss using two manufacturers’ densitometers. J Bone Miner Res 10:1796–1801PubMedCrossRef
26.
go back to reference Yang S, Fuerst T, Lu Y, Pekrul A, Wu J, Nicol E, Genant HK (1997) Changes in spine bone mineral density correlate with changes in spine area: an artifact of edge detection methods? J Bone Miner Res 12 Suppl 1:S176 Yang S, Fuerst T, Lu Y, Pekrul A, Wu J, Nicol E, Genant HK (1997) Changes in spine bone mineral density correlate with changes in spine area: an artifact of edge detection methods? J Bone Miner Res 12 Suppl 1:S176
27.
go back to reference Fox J, Miller MA, Recker RR, Bare SP, Smith SY, Moreau IA (2005) Treatment of postmenopausal osteoporotic women with parathyroid hormone 1–84 for 18 months increases cancellous bone formation and improves cancellous architecture: a study of iliac crest biopsies using histomorphometry and micro computed tomography. J Musculoskelet Neuronal Interact 5:356–357PubMed Fox J, Miller MA, Recker RR, Bare SP, Smith SY, Moreau IA (2005) Treatment of postmenopausal osteoporotic women with parathyroid hormone 1–84 for 18 months increases cancellous bone formation and improves cancellous architecture: a study of iliac crest biopsies using histomorphometry and micro computed tomography. J Musculoskelet Neuronal Interact 5:356–357PubMed
28.
go back to reference Miller MA, Bare, SP, Recker RR, Smith SY, Fox J (2007) Intratrabecular tunneling increases trabecular number at multiple skeletal locations in ovariectomized rhesus monkeys treated with parathyroid hormone 1–84. J Bone Miner Res 22 Suppl 1:S440 Miller MA, Bare, SP, Recker RR, Smith SY, Fox J (2007) Intratrabecular tunneling increases trabecular number at multiple skeletal locations in ovariectomized rhesus monkeys treated with parathyroid hormone 1–84. J Bone Miner Res 22 Suppl 1:S440
29.
go back to reference Turner CH (2002) Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 13:97–104PubMedCrossRef Turner CH (2002) Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 13:97–104PubMedCrossRef
30.
go back to reference Hildebrand T, Laib A, Müller R, Dequeker J, Rüegsegger P (1999) Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneus. J Bone Miner Res 14:1167–1174PubMedCrossRef Hildebrand T, Laib A, Müller R, Dequeker J, Rüegsegger P (1999) Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneus. J Bone Miner Res 14:1167–1174PubMedCrossRef
Metadata
Title
Effects of Treatment with Parathyroid Hormone 1–84 on Quantity and Biomechanical Properties of Thoracic Vertebral Trabecular Bone in Ovariectomized Rhesus Monkeys
Authors
J. Fox
M. K. Newman
C. H. Turner
R. E. Guldberg
A. Varela
S. Y. Smith
Publication date
01-03-2008
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 3/2008
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-008-9108-7

Other articles of this Issue 3/2008

Calcified Tissue International 3/2008 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.